

FIGURES

Figure 1



Dose	10 mg	20 mg	50 mg	100 mg
C_{max} [ng/mL]	59.8±19.2	127±45.4	375±229	840±349
AUC_{0-t} [ng/mL*h]	205±50.3	442±159	1106±694	2211±821
t_{max} [h], Median Range	1.00 0.750-2.00	1.25 0.750-2.00	1.00 0.500-2.00	1.13 0.750-2.00

Figure 2



Clinical PK data (CEC-2/BIO)		C_{max} / $IC_{(10-90)}$		
Drug level	C_{max} (≡ drug conc. at target site)	IC_{10} (8.5 ng/mL)	IC_{50} (54.3 ng/mL)	IC_{90} (208.1 ng/mL)
10 mg	59.8 ng/mL	7.0	1.1	0.3
20 mg	127.0 ng/mL	14.9	2.3	0.6
50 mg	375.0 ng/mL	44.1	6.9	1.8
100 mg	840.0 ng/mL	98.8	15.5	4.0

Figure 3




Figure 4




Figure 5




Figure 6




Figure 7



Individual patient's villous height-to-crypt depth ratio (VH:CrD)
P<.0001
P<.0001
P=0.0002
10 mg
(n=35)
P=0.0372
50 mg
(n=39)
P=0.1098
100 mg
(n=38)
P=0.1040
Placebo
(n=30)
P<.0001
VH:CrD
Screening
Final

Figure 8



Individual patient's intraepithelial lymphocyte (IEL) density
P=0.0001
P=0.0881
P=0.2823
10 mg
50 mg
100 mg
Placebo
(n=30)
CD3+ IEL density
Screening
Final

Figure 9



Celiac Disease Symptom Score (Change from Baseline)
CSI score (Change from baseline)
5
4
3
2
1
0
-1
0
2
4
6
8
10
Week
10 mg
50 mg
100 mg
Placebo

Figure 10

Celiac Disease Questionaire Score (Change from Baseline)

A.




Figure 10 continued

B.

